Your browser doesn't support javascript.
loading
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Le Du, Fanny; Carton, Matthieu; Bachelot, Thomas; Saghatchian, Mahasti; Pistilli, Barbara; Brain, Etienne; Loirat, Delphine; Vanlemmens, Laurence; Vermeulin, Thomas; Emile, George; Gonçalves, Anthony; Ung, Mony; Robert, Marie; Jaffre, Anne; Desmoulins, Isabelle; Jouannaud, Christelle; Uwer, Lionel; Marc Ferrero, Jean; Mouret-Reynier, Marie-Ange; Jacot, William; Chevrot, Michaël; Delaloge, Suzette; Diéras, Véronique.
Affiliation
  • Le Du F; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
  • Carton M; Department of Biostatistics, Institut Curie, Saint-Cloud, France.
  • Bachelot T; Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.
  • Saghatchian M; Department of Medical Oncology, Hôpital Américain, Paris, France.
  • Pistilli B; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
  • Brain E; Department of Medical Oncology, Institut Curie/Saint Cloud, Paris, France.
  • Loirat D; Department of Biostatistics, Institut Curie, Saint-Cloud, France.
  • Vanlemmens L; Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
  • Vermeulin T; Centre Henri Becquerel, Rouen, France.
  • Emile G; Department of Medical Oncology, Centre François Baclesse, Caen, France.
  • Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
  • Ung M; Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France.
  • Robert M; Department of Medical Oncology, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain, France.
  • Jaffre A; Anne jaffré Department of Medical Information, Institut Bergonié, Bordeaux, France.
  • Desmoulins I; Department of Medical Oncology, Centre Jean-Francois Leclerc, Dijon, France.
  • Jouannaud C; Department of Medical Oncology, Institut Godinot, Reims, France.
  • Uwer L; Institut de Cancérologie de Lorraine, Nancy, France.
  • Marc Ferrero J; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
  • Mouret-Reynier MA; Department of Medical Oncology, Clermont-Ferrand, France.
  • Jacot W; Department of Medical Oncology, Institut du cancer de Montpellier, Montpellier, France.
  • Chevrot M; Health Data and Partnership Department, Unicancer, Paris, France.
  • Delaloge S; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
  • Diéras V; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
Oncologist ; 28(10): e867-e876, 2023 10 03.
Article in En | MEDLINE | ID: mdl-37589218
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Chemotherapy, Adjuvant / Receptor, ErbB-2 / Trastuzumab Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Chemotherapy, Adjuvant / Receptor, ErbB-2 / Trastuzumab Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: France